Journal of cancer research and clinical oncology
-
J. Cancer Res. Clin. Oncol. · Mar 2014
Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
To investigate the role of biomarkers including serum tissue inhibitor of metalloproteinases-1 (TIMP-1), urokinase plasminogen activator receptor, vascular endothelial growth factor, and epidermal growth factor receptor in predicting pathologic response to neoadjuvant chemoradiation (NACRT) for rectal cancer. ⋯ Post-NACRT serum TIMP-1 could be used as a predictive marker of pathologic response to NACRT in rectal cancer, even in patients with clinical response.
-
J. Cancer Res. Clin. Oncol. · Jan 2014
FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
We investigated fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)-assessed metabolic tumor volume (MTV) and total lesion glycolysis (TLG) as prognostic factors in lung adenocarcinoma patients. ⋯ Assessment of MTV and TLG by FDG PET/CT in advanced lung adenocarcinoma patients provides useful information regarding prognosis.
-
J. Cancer Res. Clin. Oncol. · Jan 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
The role of olanzapine added to a dopamine antagonist and benzodiazepine for the treatment of refractory chemotherapy-induced nausea and vomiting (CINV) is incompletely characterized in all levels of chemotherapy emetogenicity. This retrospective study evaluated the efficacy of the addition of olanzapine in adults experiencing refractory CINV stratified by chemotherapy emetogenicity. ⋯ The addition of olanzapine to a dopamine antagonist and benzodiazepine demonstrated high efficacy rates for refractory CINV irrespective of chemotherapy emetogenicity. The high success rates among all groups suggests that incomplete resolution of CINV with prophylactic serotonin antagonists and breakthrough dopamine antagonists plus benzodiazepine may benefit from the addition of olanzapine regardless of gender, degree of chemotherapy emetogenicity, number of prophylactic antiemetics, or age. The trend toward greater control of emesis in women merits further investigation.
-
J. Cancer Res. Clin. Oncol. · Dec 2013
ReviewSafety and efficacy of transdermal buprenorphine for the relief of cancer pain.
This study aimed to synthesize the available evidence on the efficacy and safety of transdermal (TD) buprenorphine. ⋯ Transdermal buprenorphine has an increasing role for the relief of cancer pain. Further research in this field is needed. Multicentre studies in this field using a common protocol and strict supervision will be more practicable.
-
J. Cancer Res. Clin. Oncol. · Dec 2013
Scaling adult dose and schedule of anticancer agents to children.
Objective of this work was to extend pharmacokinetic scaling theory of the writer for bolus dosing to include the case of constant-rate i.v. dosing over fixed interval so as to allow projection of adult dose and schedule of typically administered anticancer agents to children. ⋯ Basic theory for scaling adult dose and schedule of anticancer agents to children is presented and demonstrated to be plausible in providing insight into existing and proposed pediatric treatment protocols.